$MRNA - MODERNA FALLS 12% PRE OPEN Moderna Shares Down After Report Top Vaccine Official Peter Marks Forced Out At FDA

So what I saw on the flow was right… was up over 7% on the day. @unusual_whales for the win $MRNA

$MRNA - MODERNA SEES `QUITE LARGE' REVENUE OPPORTUNITY IN CANCER: HOGE

$MRNA shares -4.1% premarket after results and guidance

$MRNA Q4 & FY25 Outlook: 🔹 Q4 Results: • EPS: -$2.91 (Missed Est. -$2.68) • Revenue: $966M (Beat Est. $942.8M, -66% y/y) • COVID-19 Vaccine Rev: $923M (In Line) • Op. Loss: -$1.25B (Est. -$1.13B, vs. $6M profit y/y) • Cash & Equiv.: $1.93B (Est. $2.12B) 🔹 FY25 Guidance: • Revenue: $1.5B-$2.5B (Est. $2.43B) • CapEx: ~$400M (Est. $468.9M) • Cost Cuts: $1B by 2025-end • Cash & Inv. (Dec 31): $9.5B Q4 loss includes $200M in non-cash charges for manufacturing resizing.

The weekly $MRNA 42C nailed the dip. Killer trade

$MRNA - MODERNA SHARES UP 4.1% PREMARKET AS U.S. AWARDS CO $590 MILLION FOR BIRD FLU VACCINE DEVELOPMENT

$MRNA - MODERNA SHARES EXTEND DECLINES PREMARKET, LAST DOWN 18%

#Upgrades - Nov 18, 2024 • $AMLX: Baird Upgrades to Outperform from Neutral - PT $11 (from $3) • $APD: UBS Upgrades to Buy from Neutral - PT $375 (from $338) • $AUTL: Goldman Sachs Upgrades to Buy from Neutral - PT $7.60 (from $7) • $BFAM: BMO Capital Upgrades to Outperform from Market Perform - PT $125 (from $137) • $CBRL: Argus Upgrades to Buy from Hold - PT $52 • $CVS: Wells Fargo Upgrades to Overweight from Equal Weight - PT $66 (from $60) • $FUTU: Morgan Stanley Upgrades to Overweight from Equalweight - PT $115 (from $70) • $HOOD: Needham Upgrades to Buy from Hold - PT $40 • $HPE: Raymond James Upgrades to Strong Buy from Outperform - PT $29 (from $23) • $MBI: KBW Upgrades to Outperform from Market Perform - PT $9 (from $6.50) • $MPWR: Loop Capital Upgrades to Buy from Hold - PT $660 • $MRNA: HSBC Upgrades to Buy from Hold - PT $58 • $PRMB: Deutsche Bank Upgrades to Buy from Hold - PT $33 (from $20) • $ROKU: Baird Upgrades to Outperform from Neutral - PT $90 (from $70) • $UFCS: Piper Sandler Upgrades to Neutral from Underweight - PT $26 (from $19)

#Downgrades - Sep 13, 2024 $ASAI: BofA Securities Downgrades to Neutral from Buy - PT $9.10 (from $13) $CPRI: Citi Downgrades to Neutral from Buy - PT $41 $CUBE: UBS Downgrades to Neutral from Buy - PT $54 (from $53) $FULC: H.C. Wainwright Downgrades to Neutral from Buy - PT $4 $GMRN: Barclays Downgrades to Underweight from Equalweight - PT $133 (from $181) $HAL: RBC Capital Downgrades to Sector Perform from Outperform - PT $37 (from $44) $MRNA: JPMorgan Downgrades to Underweight from Neutral - PT $70 (from $88) $MRNA: Jefferies Downgrades to Hold from Buy - PT $65 (from $120) $MRNA: Oppenheimer Downgrades to Perform from Outperform $NBR: Citi Downgrades to Neutral from Buy - PT $75 (from $110) $RLJ: Wells Fargo Downgrades to Underweight from Equal Weight - PT $9 (from $11) $VOYA: Raymond James Downgrades to Market Perform from Strong Buy

🔸MODERNA SHARES TUMBLE 17% TO LOWEST IN 10 MONTHS $MRNA

$MRNA MODERNA GETS MHRA AUTHORIZATION FOR UPDATED COVID VAX TARGETING